For hay fever sufferers, the end may be in sight for another year of sniffles, sneezes and itchy eyes caused by grass pollen.
But while many people are able to treat their symptoms with over the counter medications, for some sufferers, a different approach is needed to tackle the route cause.
Researchers at Imperial College London are investigating new hay fever therapies based on protein fragments from grass, which they have found can help to reduce symptoms after just three weeks of treatment.
The findings of one study, published in the journal Allergy earlier this year, showed that a short course with the peptide treatment – which could be delivered via injection over the course of four visits to the GP – was enough to reduce the symptoms of seasonal hay fever and improve patients’ quality of life.
According to Dr. Mohamed Shamji, from Imperial’s National Heart and Lung Institute and a clinical allergist, grass pollen peptide therapy could help patients who do not respond to over-the-counter medications, or who react poorly to current clinic-based treatments.
Calming the immune response
“Seasonal hay fever is a global problem and most patients seem to respond to treatments such as antihistamines, but around 20 per cent of patients do not respond to any treatment and their quality of life is affected tremendously,” explains Dr. Shamji.
“By following these patients after treatment, we have been able to demonstrate that there is a significant reduction in their symptoms and combined scores, which can last throughout the whole pollen season.”
The international team, led by researchers at Imperial College London and IMSIE in Germany, developed an immunotherapy treatment from protein fragments, or peptides, of rye grass (Lolium perenne).
These fragments cause the body to produce a mild immune response, enabling it to build up resistance to pollen exposure.
In a double blind, placebo-controlled trial, 443 patients with moderate-to-severe hay fever triggered by grass pollen received either the LLP treatment (n=329), called gp-ASIT+, or placebo (n=114).
Patients were recruited from six European countries; Belgium, Czech Republic, Germany, France, Italy and Spain.
Over the course of four visits to a clinic before the start of the pollen season, patients received an injection in each arm (eight in total) – those receiving the peptide treatment were given steadily increasing doses over the visits (a cumulative dose of 170 mcg of gp-ASIT+).
Patients recorded a composite score of their symptoms, taking into account the amount of ‘rescue medication’ needed over the course of peak grass pollen season (May to September in the UK, with peak season in June and July). Rescue medication, taken to alleviate excess hay fever symptoms, was in the form of antihistamine tablets (fexofenadine) provided by the research team.
After analysing the results, the team found that the average daily symptom score was less during the height of pollen season for those patients who had received the treatment, reducing symptom score by an average of 15.5 per cent compared with placebo.
When analysing the trend over the entire flu season, they found that the treatment reduced symptoms by 17.9 per cent on average, compared to placebo. Patients also reported significantly increased quality of life over the course of the season.
“The findings are very promising,” said Dr. Shamji. “With this new peptide treatment, patients who do not respond to available treatments could potentially attend clinic over a number of weeks to receive a handful of injections and remain relatively symptom free over the pollen season.”
The researchers add that there were a number of limitations to the latest study, including incomplete questionnaire data outside of peak pollen season – due to patient compliance – as well as the exclusion of some patients due to the influence of other pollen sources, including birch. They also add that longer-term follow up data is needed for adverse reactions and dose adjustments for patients.
However, they are confident that a short course of therapy with gp-ASIT+ before the start of pollen season could improve patient compliance to treatment regimens, rather than pills throughout the season, and be more efficient than standard immunotherapy.
More information: R. Mösges et al. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial, Allergy (2018). DOI: 10.1111/all.13433
Journal reference: Allergy search and more info website
Provided by: Imperial College London search and more info website